Compare Salesforce Inc (CRM) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Medtronic PLC — how do they compare? Salesforce Inc trades at $228.53 (market cap $187.48B), while Medtronic PLC trades at $88.61 (market cap $112.24B). The key difference: Salesforce Inc is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Medtronic PLC for 63 Days on average.
| CRM | MDT | |
|---|---|---|
Market Cap | $187.48B | $112.24B |
Volume | 6,155,822 | 105,663,236 |
Sector | Technology | Health |
52-Week High | $266.23 | $105.35 |
52-Week Low | $150.12 | $73.75 |
Typical Hold Time | 89 Days | 63 Days |
Enterprise Value | $217.82B | $131.58B |
Dividend Yield | 0.77% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $224.56, down 0.19% on the day, amid a broader software sector sell-off driven by AI disruption concerns. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $5.90 vs. $3.27 expected) and robust profitability (77.28% gross margin, 21.99% net margin). Technical indicators signal bearish momentum with resistance at $227 and support at $222. Recent news highlights AI-driven volatility but also underscores Salesforce's positioning as an Agentic AI beneficiary.
Outlook: Salesforce's discounted valuation (P/E 20.86 vs. historical averages) and AI monetization growth (Agentforce ARR up 200% YoY) present a buying opportunity, though near-term risks include sector-wide pressure and macroeconomic uncertainty. Analyst consensus remains strongly bullish with a $271.91 price target, suggesting ~21% upside.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
